|
Other Liabilities
|
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Oct. 31, 2012
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities Disclosure [Text Block] |
Note 7 – Other Liabilities Other liabilities consist of the following as of:
During the three months ended October 31, 2012, the Company entered into a five year capital lease arrangement for lab equipment aggregating $768 for the clinical labs segment. Future minimum annual payments under the capital lease net of interest of $76 aggregates $768, including a short term debt portion of $149 included in other current liabilities. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||